Could a simple supplement ease a rare lung disease?
NCT ID NCT06176118
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a dietary supplement called 2-HOBA in 12 adults with pulmonary arterial hypertension (PAH), a condition where high blood pressure in the lungs strains the heart. Participants take the supplement three times daily for 12 weeks. The study checks if 2-HOBA improves heart function and reduces signs of disease, building on earlier positive results.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 2-HOBA (a dietary supplement)
- What this could lead to
- If it works, this could point toward a new supplement-based treatment to help control pulmonary arterial hypertension and improve heart function.
- What could go wrong
- This is a very small early-phase trial with only 12 participants, so results may not apply broadly. The supplement's effectiveness and safety are still unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Could a gut bacteria transplant ease a rare lung disease?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests